Clinical Trials for Immatics Biotechnologies

Explore 2 clinical trials worldwide

Showing 1-2 of 2 trials

Active filters:Status: Recruiting, Active, not recruiting, Enrolling by invitation, Not yet recruitingSponsor: Immatics Biotechnologies

Clinical Trials (2)

NCT05958121
IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors
PHASE1/PHASE2Recruiting
145 participants
Started: Aug 9, 2023 · Completed: Sep 30, 2027
4 conditions1 sponsor24 locations
NCT05359445
IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor
PHASE1Recruiting
95 participants
Started: May 19, 2022 · Completed: Dec 31, 2029
4 conditions1 sponsor23 locations